Skip to main content

Advertisement

Table 2 Clinical trials about PARP inhibitor plus chemotherapy

From: Advances and perspectives of PARP inhibitors

Combination therapyTrialCancerPhaseStatus
Rucaparib and CisplatinNCT01074970Breast cancer2Active, not recruiting
Olaparib, Paclitaxel, and CarboplatinNCT03150576Breast cancer2/3Recruiting
PF-01367338 and CarboplatinNCT01009190Advanced solid tumors1Completed
BSI-201 and IrinotecanNCT01173497Breast cancer2Completed
BSI-201, Carboplatin, and GemcitabineNCT00813956Breast cancer2Completed
Veliparib and Topotecan HydrochlorideNCT01012817Multiple solid tumors1/2Active, not recruiting
Olaparib, Cediranib, and Platinum-based ChemotherapyNCT02855697Ovarian cancer1Recruiting
Olaparib and Platinum agentsNCT02489006Ovarian cancer2Recruiting
Iniparib, Carboplatin, and GemcitabineNCT00540358Breast cancer2Completed
AZD2281 and Liposomal DoxorubicinNCT00628251Ovarian cancer2Completed
Olaparib, Temozolomide, and IrinotecanNCT01858168Ewing’s sarcoma1Recruiting
BMN-673, Temozolomide, and Irinotecan HydrochlorideNCT02049593Advanced solid tumors1Active, not recruiting
AZD2281 and TopotecanNCT00516438Advanced solid tumors1Completed
AZD2281 and GemcitabineNCT00515866Pancreatic cancer1Completed
AZD2281 and DacarbazineNCT00516802Melanoma1Completed
Veliparib, VX-970, and CisplatinNCT02723864Advanced solid tumors1Recruiting
Niraparib and TemozolomideNCT03830918Small cell lung cancer1/2Recruiting
Rucaparib and Platinum-based ChemotherapyNCT02855944Ovarian cancer3Recruiting
BGB-290 and TemozolomideNCT03914742Gliomas1/2Not yet recruiting
AZD2281, Carboplatin, and PaclitaxelNCT00516724Multiple solid tumors1Active, not recruiting
Talazoparib, Irinotecan, and TemozolomideNCT02392793Childhood solid tumors1Active, not recruiting
AZD2281, Cisplatin, and GemcitabineNCT00678132Solid tumor cancers1Completed
Talazoparib and TemozolomideNCT03672773Small cell lung cancer2Recruiting
Veliparib and TemozolomideNCT01139970Acute leukemia1Active, not recruiting
Veliparib and DoxorubicinNCT01145430Ovarian cancer1Completed
Talazoparib and DecitabineNCT02878785Acute leukemia1/2Recruiting
Olaparib and TemozolomideNCT03880019Uterine leiomyosarcoma2Not yet recruiting
BGB-290 and TemozolomideNCT03749187Gliomas1Recruiting
Veliparib, Fluorouracil, and Irinotecan HydrochlorideNCT02890355Pancreatic cancer2Active, not recruiting
Olaparib and TemozolomideNCT03212742Gliomas1/2Recruiting
ABT-888 and Topotecan HydrochlorideNCT00553189Solid tumors and lymphomas1Completed
Olaparib and TemozolomideNCT01390571Glioblastoma1Completed
Iniparib, Gemcitabine, and CisplatinNCT01086254Non-small cell lung cancer2Completed
Rucaparib, Docetaxel, and CarboplatinNCT03442556Prostate cancer2Recruiting
Veliparib, Carboplatin, and PaclitaxelNCT00535119Advanced solid cancer1Completed
Veliparib, Carboplatin, Paclitaxel, and PemetrexedNCT02944396Non-small cell lung cancer1/2Active, not recruiting
Veliparib and CyclophosphamideNCT01351909Breast cancer1Active, not recruiting
ABT-888 and TemozolomideNCT01009788Breast cancer2Active, not recruiting
BSI-201, Gemcitabine, and CarboplatinNCT01045304Breast cancer2Completed
Veliparib and TemozolomideNCT03581292Glioma2Recruiting
BSI-201, Gemcitabine, and CarboplatinNCT01213381Advanced solid tumors1Completed
Olaparib, Paclitaxel, Topotecan Hydrochloride, and DoxorubicinNCT02502266Ovarian cancer2/3Recruiting
Olaparib and PaclitaxelNCT02789332Breast Cancer2Recruiting
Veliparib, Carboplatin, Paclitaxel, and FOLFIRINCT02033551Solid Tumors1Completed
Veliparib, Carboplatin, Cisplatin, Fluorouracil, Hydroxyurea, and PaclitaxelNCT01711541Head and neck cancer1/2Active, not recruiting
Veliparib, Gemcitabine, and CarboplatinNCT02860819Testicular germ cell cancer2Recruiting
Veliparib, Carboplatin, and PaclitaxelNCT02264990Non-small cell lung cancer3Active, not recruiting
Veliparib and CarboplatinNCT01149083Breast cancer2Active, not recruiting
Veliparib and Mitomycin CNCT01017640Solid tumors1Completed
Veliparib, Paclitaxel, and CisplatinNCT01281852Cervical cancer1Completed
Veliparib, Paclitaxel, Carboplatin, and Bevacizumab,NCT00989651Ovarian cancer1Active, not recruiting
ABT-888 and TemozolomideNCT00994071Nervous system tumor1Completed
Veliparib and CisplatinNCT02595905Breast cancer2Recruiting
Veliparib, Paclitaxel, and CarboplatinNCT01366144Solid tumors1Suspended
Veliparib, Gemcitabine Hydrochloride, and CisplatinNCT01585805Pancreatic cancer2Active, not recruiting
Veliparib, Cyclophosphamide, and Doxorubicin HydrochlorideNCT00740805Solid tumors or non-hodgkin lymphoma1Active, not recruiting
Veliparib, Topotecan Hydrochloride, and CarboplatinNCT00588991Acute leukemia, high-risk myelodysplasia, and myeloproliferative disorders1Active, not recruiting
Veliparib, Bendamustine Hydrochloride, and RituximabNCT01326702Lymphoma, multiple myeloma, solid tumors1/2Completed
Veliparib, Cisplatin, and Vinorelbine DitartrateNCT01104259Breast cancer1Completed
  1. The details of the table are obtained from https://www.clinicaltrials.gov/